登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science，6月10日，Detection of SARS-CoV-2 in Fecal Samples from Patients with Asymptomatic and Mild COVID-19 in Korea》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-11

  • Detection of SARS-CoV-2 in Fecal Samples from Patients with Asymptomatic and Mild COVID-19 in Korea

    Author links open overlay panelSoo-kyungParkMD1Chil-WooLeeMS2Dong-IlParkMD1Hee-YeonWooMD3Hae SukCheongMD4Ho CheolShinMD5KwangsungAhnPhD6Min-JungKwonMD3∗Eun-JeongJooMD4∗

    Show more

    https://doi.org/10.1016/j.cgh.2020.06.005

    Abstract:

    Background & Aims

    Although COVID-19 is characterized by fever and respiratory symptoms, some patients have no or mild symptoms. SARS-CoV-2 has been detected in feces of patients. We investigated gastrointestinal symptoms and shedding of virus into feces of patients with asymptomatic or mild COVID-19.

    Methods

    We collected data from 46 patients (median age, 26 years; 46% men) with asymptomatic or mild COVID-19 (without fever and pneumonia) and prolonged respiratory shedding of SARS-CoV-2, quarantined from April 4, 2020 through April 24, 2020 in Korea. Respiratory specimens included upper respiratory specimens (nasopharyngeal and oropharyngeal swabs) and lower respiratory specimens (sputum) and were collected twice per week. The median interval between COVID-19 diagnosis to the start of fecal sample collection was 37 days (range, 29–41); 213 stool specimens were collected from 46 patients. We used real-time reverse transcription PCR to detect SARS-CoV-2 in the respiratory and fecal specimens.

  • 原文来源：https://www.sciencedirect.com/science/article/abs/pii/S1542356520307771
106浏览量
原文链接
相关报告

  • 《Nature，6月19日，In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-20
    • In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19 Inga-Marie Schaefer, Robert F. Padera, Isaac H. Solomon, Sanjat Kanjilal, Mark M. Hammer, Jason L. Hornick & Lynette M. Sholl Modern Pathology (2020) Abstract Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has led to a global public health crisis. In elderly individuals and those with comorbidities, COVID-19 is associated with high mortality, frequently caused by acute respiratory distress syndrome. We examine in situ expression of SARS-CoV-2 in airways and lung obtained at autopsy of individuals with confirmed COVID-19 infection. Seven autopsy cases (male, N = 5; female, N = 2) with reverse transcriptase-polymerase chain reaction (RT-PCR)-confirmed SARS-CoV-2 infection and a median age of 66 years (range, 50–77 years) were evaluated using a rabbit polyclonal antibody against SARS Nucleocapsid protein in correlation with clinical parameters. The median time from symptom onset to death was 9 days (range, 6–31 days), from hospitalization 7 days (range, 1–21 days), from positive RT-PCR 7 days (range, 0–18 days), and from intensive care unit admission defining onset of respiratory failure 3 days (range, 1–18 days). Chest imaging identified diffuse airspace disease in all patients corresponding to acute and (N = 5) or organizing (N = 2) diffuse alveolar damage (DAD) on histologic examination.
    41浏览量
    原文链接

  • 《MedRxiv，3月20日，SARS-CoV-2 specific antibody responses in COVID-19 patients》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-22
    • SARS-CoV-2 specific antibody responses in COVID-19 patients NISREEN M.A. OKBA, Marcel A Muller, Wentao Li, Chunyan Wang, Corine H. GeurtsvanKessel, Victor M. Corman, Mart M. Lamers, Reina S. Sikkema, Erwin de Bruin, Felicity D. Chandler, Yazdan Yazdanpanah, Quentin Le Hingrat, Diane Descamps, Nadhira Houhou-Fidouh, Chantal B. E. M. Reusken, Berend-Jan Bosch, Christian Drosten, Marion P.G. Koopmans, Bart L. Haagmans doi: https://doi.org/10.1101/2020.03.18.20038059 Abstract A new coronavirus, SARS-CoV-2, has recently emerged to cause a human pandemic. Whereas molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are important for contact tracing, identifying the viral reservoir and epidemiological studies. Here, we developed serological assays for the detection of SARS-CoV-2 neutralizing, spike- and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed infections of SARS-CoV-2, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    153浏览量
    原文链接